USPSTF Prevention TaskForce vs Probiotic Guide USA

The Prevention TaskForce (formerly ePSS) is an application designed and developed by the U.S. Department of Health & Human Services (HHS), Agency for Healthcare Research and Quality (AHRQ), the Nation's lead Federal agency for research on health care quality, costs, outcomes and patient safety. It was developed by AHRQ to support the independent U.S. Preventive Services Task Force (USPSTF). The USPSTF is an independent, volunteer panel of national experts in prevention and evidence-based medicine. AHRQ provides support to the USPSTF. The Prevention TaskForce application was developed to assist primary care clinicians identify the screening, counseling, and preventive medication services that are appropriate for their patients. The Prevention TaskForce information is based on the current recommendations of the U.S. Preventive Services Task Force (USPSTF) and can be searched by specific patient characteristics, such as age, sex, and selected behavioral risk factors. When using this tool please read the specific recommendation to determine if the preventive service is appropriate for your patient. This tool is not meant to replace clinical judgment and individualized patient care. *Application downloads and data updates require internet connectivity

WHAT is this: A Practice Tool to Assist with Clinical Decision Making for Appropriate Probiotic Therapy for Your Patients WHO is the intended user: This Clinical Guide is designed to translate scientific evidence available for probiotic products to practical, clinically relevant information. It is intended to be used as clinical decision-making tool, enabling clinicians to easily select the appropriate product, dose, and formulation for a specific indication. WHY is this needed: Currently, the body of evidence for probiotic interventions is growing along with popular demand for these products. There is evidence to support the use of probiotic products for a variety of indications beyond gut health, however applications and results are strain-specific. Due to frequent changes in commercial availability of probiotic strains, new published evidence and growing research, an annual review and updates of this Clinical Guide have been conducted since 2008. A general lack of adverse effects attributable to probiotics supports the wide use of these products, but ongoing investigation is recommended.